{"url_path":"/sec/cgtx/8-k/2026-05-21/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1455365/0001104659-26-064863-index.html","accession_number":"0001104659-26-064863","cik":"0001455365","ticker":"CGTX","issuer_name":"COGNITION THERAPEUTICS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1455365/0001104659-26-064863-index.html","primary_entity_key":"0001455365","primary_entity_name":"COGNITION THERAPEUTICS INC"},"word_count":314,"has_tables":true,"body_markdown":"false\n0001455365\n\n0001455365\n\n2026-05-21\n2026-05-21\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED\nSTATES\nSECURITIES AND EXCHANGE COMMISSION****Washington, DC 20549**\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT\nPursuant to Section 13 or 15(d)\nof the Securities Exchange Act of 1934**\n\n \n\nDate of Report (Date of earliest event\nreported): May 21, 2026\n\n \n\n**Cognition\nTherapeutics, Inc.**\n\n(Exact name of registrant as specified in its\ncharter)\n\n \n\n**Delaware**\n \n**001-40886**\n \n**13-4365359**\n\n(State\nor other jurisdiction of\n\nincorporation or organization)\n \n(Commission File Number)\n \n(I.R.S.\nEmployer\n\nIdentification No.)\n\n \n\n**2500 Westchester Ave.****Purchase****,\nNY**\n \n**10577**\n\n(Address\nof principal executive offices)\n \n(Zip\nCode)\n\n \n\nRegistrant’s telephone number, including\narea code: **(412****)\n481-2210**\n\n \n\n**Not\nApplicable**(Former name or former address, if changed since last report)\n\n \n\nCheck the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see\nGeneral Instruction A.2. below):\n\n \n\n¨\nWritten\ncommunications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n \n\n¨\nSoliciting\nmaterial pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n \n\n¨\nPre-commencement\ncommunications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n \n\n¨\nPre-commencement\ncommunications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\n**Title\nof Each Class**\n \n**Trading\nSymbol**\n \n**Name\nof Exchange on Which\nRegistered**\n\nCommon\nStock, par value $0.001 per share\n \nCGTX\n \nThe\nNasdaq Stock Market LLC\n\n \n\nIndicate by check mark whether the registrant is\nan emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2\nof the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging\ngrowth company x\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨"}